Overview

Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium

Status:
Unknown status

Trial end date:
2021-03-01

Target enrollment:

Participant gender:

Summary

The trial will recruit up to 120 patients; 90 with ovarian clear cell carcinoma and up to 30 with endometrial clear cell carcinoma. Patients will be randomised between chemotherapy and Nintedanib 200mg twice daily oral administration (PO) continuously. The primary diagnosis must be histologically confirmed and central pathological review of the presenting tumour or biopsy of relapsed disease must find at least 50% clear cell carcinoma with no serous differentiation

Phase:

Phase 2

Details

Lead Sponsor:

NHS Greater Glasgow and Clyde

Collaborators:

ARCAGY/ GINECO GROUP
Boehringer Ingelheim
Cancer Research UK
European Organisation for Research and Treatment of Cancer - EORTC
Nordic Society for Gynaecologic Oncology
Nordic Society of Gynaecological Oncology - Clinical Trials Unit

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Doxorubicin
Liposomal doxorubicin
Nintedanib
Paclitaxel
Topotecan